• Home
  • NEW DAY MEDICINE
  • 12 (86) 2025
  • 113 -12 (86) 2025 - Tosheva Kh.B., Gadayev A.G., Boboev A.T., - THE SIGNIFICANCE OF β1-TRANSFORMING GROWTH FACTOR GENE rs1800473 POLYMORPHISM IN THE DEVELOPMENT OF CARDIORENAL SYNDROME

113 -12 (86) 2025 - Tosheva Kh.B., Gadayev A.G., Boboev A.T., - THE SIGNIFICANCE OF β1-TRANSFORMING GROWTH FACTOR GENE rs1800473 POLYMORPHISM IN THE DEVELOPMENT OF CARDIORENAL SYNDROME

THE SIGNIFICANCE OF β1-TRANSFORMING GROWTH FACTOR GENE rs1800473 POLYMORPHISM IN THE DEVELOPMENT OF CARDIORENAL SYNDROME

Tosheva Kh.B. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Gadayev A.G. - Tashkent State Medical University

Boboev A.T. - Republican Specialized Scientific and Practical Medical Hematology Center

Turakulov R.I. - Tashkent State Medical University

Resume

The significance of TGF-β1 gene rs1800473 polymorphism in the pathogenesis of cardiorenal syndrome (CRS) developed on the background of chronic heart failure (CHF) was studied. The study included 100 CRS+ patients, 100 CRS- patients, and 40 healthy individuals. Results showed that the TT genotype occurred 1.8 times less frequently in the CRS+ group compared to the control group (OR=0.4, p=0.002), indicating its protective effect. The CC genotype occurred 2.4 times more frequently (OR=2.84, p=0.009), increasing disease risk. Treatment efficacy with dapagliflozin was higher in TT genotype carriers. The TGF-β1 rs1800473 polymorphism is an important genetic marker for predicting CRS development and treatment efficacy.

Keywords: TGF-β1, rs1800473, gene polymorphism, cardiorenal syndrome, chronic heart failure, fibrosis, SGLT2 inhibitors.

First page

616

Last page

622

For citation:Tosheva Kh.B., Gadayev A.G., Boboev A.T., Turakulov R.I. - THE SIGNIFICANCE OF β1-TRANSFORMING GROWTH FACTOR GENE rs1800473 POLYMORPHISM IN THE DEVELOPMENT OF CARDIORENAL SYNDROME//New Day in Medicine 12(86)2025 616-622 https://newdayworldmedicine.com/en/new_day_medicine/12-86-2025

List of References

  1. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. //Eur Heart J. 2010;31(6):703-11.
  2. Prastaro M, Nardi E, Paolillo S, et al. Cardiorenal syndrome: Pathophysiology as a key to the therapeutic approach in an under-diagnosed disease. //J Clin Ultrasound. 2022;50(8):1110-1124.
  3. Cruz DN, Bagshaw SM. Heart-kidney interaction: epidemiology of cardiorenal syndromes. //Int J Nephrol. 2010;2011:351291.
  4. Hatamizadeh P, Fonarow GC, Budoff MJ, et al. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. //Nat Rev Nephrol. 2013;9(2):99-111.
  5. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. //Nat Rev Nephrol. 2016;12:325-338.
  6. Martelossi Cebinelli GC, Paiva Trugilo K, Badaró Garcia S. TGF-β1 functional polymorphisms: a review. //Eur Cytokine Netw. 2016;27(4):81-89.
  7. Barsova RM, Titov BV, Matveeva NA, et al. TGF-B1 gene involvement in myocardial infarction susceptibility. //ACTA Nature. 2012;4(2):74-9.
  8. Stadtlober NP, Flauzino T, et al. TGFB1 +869 T>C (rs1800470) variant is independently associated with susceptibility in patients with systemic lupus erythematosus. Autoimmunity. 2021;54:569-575.
  9. López-Hernández FJ, López-Novoa JM. Role of TGF-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012;347:141-154.
  10. Kim Y, Lee C. The gene encoding transforming growth factor β1 confers risk of ischemic stroke and vascular dementia. Stroke. 2006;37:2843-5.

    file

    download